Tizanidine implant - Delpor
Alternative Names: DLP-208Latest Information Update: 21 Sep 2023
At a glance
- Originator Delpor
- Class Antispastics; Benzothiazoles; Imidazolines; Muscle relaxants; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Muscle spasticity
Most Recent Events
- 05 Jul 2023 Tizanidine implant - Delpor is available for licensing as of 05 Jul 2023. https://delpor.com/
- 05 Jul 2023 Preclinical trials in Muscle spasticity in USA (SC) before July 2023 (Delpor website, July 2023)